A Randomized, Multicenter, Double-Blind Phase III Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib For the Treatment of Patients with ER +, HER2 - Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease
Palbociclib After CDK and Endocrine Therapy PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy